Latest news for Relief Therapeutics (OTC:RLFTY) Stock

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Biotech

News

Penny Stocks

Health Care

Movers

Trading Ideas

General

NRXP

RLFTF

RLFTY

Relief Therapeutics Holding SA&#39;s (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the 

FDA Denies Breakthrough Tag For NRx Pharma&#39;s COVID-19 Candidate

RELIEF THERAPEUTICS S/ADR by RELIEF THERAPEUTICS HLDG AG

Relief Therapeutics Holding SA

WIIM

Conduit Pharmaceuticals shares are trading lower after the company board approved a 1-for-100 reverse stock split.

B of A Securities analyst Wamsi Mohan maintains TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) with a Buy and raises the price target from $167 to $170.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on TE Connectivity, Raises Price Target to $170

QNRX

Quoin Pharmaceuticals shares are trading higher after the company announced it advanced its Netherton syndrome treatment and is partnering with Skinvisible to seek FDA-approved topical innovation.

Shares of Li-Metal batteries manufacturer SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) are trading higher in premarket on Thursday.
SES AI has signed contracts valued at up to $10 million with two prominent global OEM partners, marking a milestone in utilizing AI for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43155807/ses-ai-signs-contracts-totaling-up-to-10-million-to-develop-ai-enhanced-li-metal-and-li-ion-batter" rel="noreferrer noopener">discovery of battery materials.</a>
These agreements aim to develop electrolyte materials for Li-Metal and Li-ion batteries in automotive applications.
SES AI said that a portion of the revenue from these contracts will be recognized in the fourth quarter of 2024, with the rest expected to be acknowledged by mid-2025.
These latest agreements with OEM partners build on the company&#8217;s prior announcement of the first battery to use an electrolyte material discovered through its AI-based Molecular Universe project.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/43127666/uber-eats-partners-with-home-depot-for-on-demand-deliveries" rel="noreferrer noopener">Uber Eats Partners With Home Depot For On-Demand Deliveries</a>
&#8220;These new contracts with our automotive OEM partners are applying our AI-discovered electrolytes for Li-Metal B-sample developments and for the first time with mature Li-ion batteries already in commercial use,&#8221; said Founder and CEO Qichao Hu.
&#8220;We believe this new revenue stream and these contracts validate and accelerate the commercial use of AI for Science for battery material discovery in automotive applications.&#8221;
Price Action: SES shares are trading higher by 20% at $0.9975 in premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43121964/adidas-sees-solid-gains-in-q4-looks-to-expand-market-share" target="_blank" rel="noreferrer noopener">Adidas Sees Solid Gains In Q4, Looks To Expand Market Share</a></li>
</ul>
Image via Shutterstock.

Equities

Contracts

SES Secures ~$10M In AI-Powered Battery Contracts; Stock Jumps

Wolfe Research analyst Steve Fleishman downgrades FirstEnergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades FirstEnergy to Peer Perform

B of A Securities analyst Christopher Nardone maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Neutral and raises the price target from $182 to $217.

DECK

B of A Securities Maintains Neutral on Deckers Outdoor, Raises Price Target to $217

Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) disclosed that its Board of Directors has approved a plan to separate its Electrical Distribution Systems (EDS) business from Aptiv, creating two <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43124298/aptiv-unplugs-eds-spin-off-aims-to-supercharge-electrification-automation-and-ai">independent entities</a>.
Aptiv also reaffirmed its 2024 outlook, with a fourth-quarter earnings report scheduled for February 6, 2025. While reporting third-quarter results in October, Aptiv said it expects FY24 adjusted earnings per share in the range of $6.00-$6.30 ($6.12 estimate) and net sales of $19.60 billion-$19.90 billion ($19.68 billion estimate).
Kevin Clark, Aptiv's Chairman and CEO, emphasized that the separation is part of the company's broader transformation strategy.
"Following completion of the transaction, Aptiv will have a portfolio of advanced software and hardware technologies and highly engineered, mission-critical products that are aligned with global mega trends fueling growth in diverse end markets," Clark said.
Aptiv's shares gained 1.5% to close at $62.73 on Wednesday.
These analysts made changes to their price targets on Aptiv following the announcement.
<ul>
<li>Piper Sandler analyst Alexander Potter upgraded Aptiv from Underweight to Neutral and raised the price target from $53 to $65.</li>
<li>Baird analyst David Leiker maintained the stock with a Neutral and raised the price target from $70 to $75.</li>
</ul>
Considering buying APTV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175-1024x596.png" alt="" class="wp-image-746807" style="width:503px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175-1024x596.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175.png 1086w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Pre-Market Outlook

Markets

APTV

These Analysts Boost Their Forecasts On Aptiv

B of A Securities analyst Wamsi Mohan maintains Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) with a Neutral and raises the price target from $75 to $85.

B of A Securities Maintains Neutral on Amphenol, Raises Price Target to $85

Citigroup analyst Christopher Allen reinstates Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Buy and announces $30 price target.

Initiation

Citigroup Reinstates Buy on Blue Owl Cap, Announces $30 Price Target

B of A Securities analyst Tim Anderson maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and lowers the price target from $160 to $159.

B of A Securities Maintains Neutral on Johnson & Johnson, Lowers Price Target to $159

VIGL

Vigil Neuroscience shares are trading higher after the company reported data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimer's disease.

Looking Ahead to 2025
As we enter 2025, we are excited to build on this momentum. Our focus remains on:
<ul>
<li>Identifying key opportunities to advance (Z)-endoxifen into registrational clinical trials with the goal of advancing (Z)-endoxifen to the market in the quickest way possible. This is our company's top priority, and we commit to communicating our progress on this goal in the first quarter of this year.</li>
<li>Amplifying our ongoing business development efforts to ensure women globally have the opportunity to benefit from (Z)-endoxifen.</li>
<li>Deepening collaborations with industry leaders and advocacy groups to broaden the impact of our work.
<ul>
<li>Extending our track record of financial strength that will position us to support our long-term growth.</li>
</ul>
</li>
</ul>

ATOS

Atossa Therapeutics Says Z-Endoxifen To Enter Registrational Clinical Trials In 2025; Updates On Progress Expected Q1; Global Business Development Efforts Amplified; Industry Partnerships Deepened; Financial Strength For Long-Term Growth Emphasized

B of A Securities analyst Joanna Gajuk maintains Concentra Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) with a Buy and raises the price target from $24 to $25.

B of A Securities Maintains Buy on Concentra Group Holdings, Raises Price Target to $25

McCormick &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) reported&nbsp;fourth-quarter sales growth of 3% year-on-year to $1.798 billion, beating the analyst consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43155089/mccormick-reports-strong-2024-financial-results-and-provides-2025-outlook" rel="noreferrer noopener">estimate of $1.77 billion</a>.
Flavor Solutions segment sales grew by 1%, with minimal impact from currency. Consumer segment sales increased 4%.
Gross profit was $722.2 million, with the margin expanding 20 basis points Y/Y to 40.2%.
Operating income rose 3% to $306.2 million and the operating margin remained flat at 17%.
Adjusted EPS of $0.80 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus estimate of $0.77.</a>
McCormick held $186.1 million in cash and equivalents as of November 30, 2024. The company generated an operating cash flow of $922 million in FY24.
&#8220;We are pleased to report strong performance for both fourth quarter and fiscal year 2024, an important year for McCormick, in which we built momentum and strengthened our leadership, returning to differentiated and sustainable volume-led growth,&#8221; said Chairman, President, and CEO Brendan M. Foley.
&#8220;Our strategic investments in core categories enabled us to drive positive volume growth, expand our margins, and deliver robust earnings growth.&#8221;
Outlook: McCormick sees FY25 sales growth of 0% – 2% as reported and 1%&nbsp;&#8211;&nbsp;3% in constant currency. The company expects an adjusted EPS of $3.03 – $3.08 versus the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">estimate of $3.11.</a>
Price Action: MKC shares are trading higher by 2.29% at $71.55 in premarket at last check Thursday.

Earnings

Guidance

McCormick Posts 3% Sales Growth In Q4 As Consumer Demand Rise

SES AI shares are trading higher after the company announced it secured two contracts worth $10 million in total.

The OLB Group, Inc., (NASDAQ:<a href="https://www.benzinga.com/stock/OLB#NASDAQ">OLB</a>), a diversified Fintech eCommerce merchant services provider and Bitcoin mining enterprise, announced today the introduction of a 3D Secure (3DS)  Access Control Service to enhance security for the Company's proprietary Card-Not-Present (CNP)  payment gateway, SecurePay&#x2122;. The Company has integrated and certified SecurePay with major card brands such as Visa, MasterCard and Discover for 3D Secure services.
Key features of SecurePay's 3D Secure solution:
Enhanced Fraud Prevention: OLB's 3DS gateway minimizes the likelihood of fraudulent transactions by implementing real-time authentication protocols.
Enhanced Customer Trust: By providing an additional layer of security, customers feel more assured about their online transactions, which may result in higher conversion rates.
Liability Shift: Using 3DS shifts the liability for fraudulent transactions from merchants to card issuers.
Enhanced fraud protection with dynamic risk rules
Responsibility for chargeback liabilities transitions from businesses to card issuers for authenticated transactions.
Global Acceptance: OLB's 3DS gateway is compatible with major card providers globally, ensuring secure international transactions.
Regulatory Compliance: The system ensures adherence to industry standards like PCI DSS, meeting legal and financial regulations.
Seamless Integration: Facilitates easy implementation with current e-commerce platforms, thereby reducing any potential disruptions to the user experience.
Integration with SecurePay's Ecosystem: As part of OLB Financial Technologies, the 3DS solution provides integration with other SecurePay products and services.
By using this advanced 3D Secure gateway, OLB ensures a safe, efficient, and trustworthy online shopping environment for both merchants and customers.
Mobile Optimization: Supports modern, user-friendly authentication methods for a smooth mobile shopping experience.
3D Secure (3DS) is a global authentication protocol designed to add an extra layer of security to online credit and debit card transactions. Originally developed by Visa and Mastercard, it is now used by major card networks to reduce fraud and enhance the safety of eCommerce payments.

OLB Group Introduces 3D Secure Access Control For SecurePay; Integrates Visa, MasterCard, Discover For Enhanced Fraud Prevention, Liability Shift, Compliance, And Global eCommerce Security.

Baird analyst Colin Sebastian maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Outperform and lowers the price target from $175 to $158.

Baird Maintains Outperform on Electronic Arts, Lowers Price Target to $158

Data shared from phase II NEO trial highlights Guardant Reveal&#x2122; as a decision tool to support organ preservation in rectal cancer
Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing the benefits of Guardant's precision oncology tools across cancer screening, recurrence monitoring, treatment selection and therapy development at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, January 23-25, 2025.
Key focus areas in Guardant's co-authored abstracts and collaborator presentations utilizing Guardant products include the impact of mutations on treatment response in colorectal cancer and biliary tract cancers, and additional support for the benefits of blood-based screening in colorectal, gastric and esophageal cancers. A rapid oral presentation will feature data from the phase II NEO trial highlighting Guardant Reveal as a decision tool to support organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision and observation.

Guardant Health Presents Phase II NEO Trial Data On Guardant Reveal Tool For Organ Preservation In Node-Negative Rectal Cancer At The ASCO GI Symposium

Citigroup analyst Andrew Kaplowitz maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Neutral and raises the price target from $361 to $437.

Citigroup Maintains Neutral on GE Vernova, Raises Price Target to $437

Sellas Life Sciences shares are trading higher after the company announced interim analysis results from its Phase 3 REGAL trial of GPS in acute myeloid leukemia.

Press Releases

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

Relief Therapeutics

Relief Therapeutics Holding SA&#39;s&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RLFTF#OTC">RLFTF</a>) collaborating partner&nbsp;NRx Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) has announced that the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/11/ac24268379/relief-reports-that-its-u-s-collaboration-partner-has-announced-the-u-s-food-and-drug-administrat" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA has denied Breakthrough Therapy Designation</a>&nbsp;for aviptadil.&nbsp;

<ul>
	<li>NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.</li>
	<li>Related content:&nbsp;Benzinga&#39;s Full&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/calendars/fda#historical" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">FDA Calendar</a>.</li>
	<li>Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.&nbsp;</li>
	<li>Therefore, the denial does not impede NRx&#39;s ability to seek drug approval.</li>
	<li>Relief&#39;s lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).</li>
	<li>It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.&nbsp;</li>
	<li>Related Link:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/11/24043451/nrx-pharmas-covid-19-candidate-receives-fda-review-for-manufacturing-information" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">NRx Pharma&#39;s COVID-19 Candidate Receives FDA Review For Manufacturing Information</a>.</li>
	<li>Price Action:&nbsp;NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.</li>
</ul>

Comments

Relief Therapeutics

News

Latest news for Relief Therapeutics (OTC:RLFTY) Stock

Wednesday, November 24, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga